Isomorphic Labs has secured $5 billion in Series C funding to advance its drug candidates toward clinical trials. The round was co-led by Greenoaks and Sequoia Capital, while new participant Andreessen Horowitz joined existing backers including Alphabet divisions GV and Capital G, Thrive Capital, MGX, Temasek, and the UK Sovereign AI Fund. The company operates an artificial intelligence engine for drug design that draws on simulation models to explore chemical properties. This work extends DeepMind’s AlphaFold protein-folding system, which predicts three-dimensional protein structures from genetic sequences. The platform has reported positive preclinical results in oncology and immunology and holds agreements with pharmaceutical companies such as Eli Lilly, Novartis, and Johnson & Johnson. The capital will support further development of the design engine and expansion into additional therapeutic areas. This funding follows a $2.1 billion Series B round in May and marks the company’s first raise since founder Demis Hassabis stepped away from his role at DeepMind to focus entirely on drug discovery. Hassabis now serves as chairman at DeepMind, while John Jumper, who previously directed the lab, also holds a senior position. The firm did not disclose its current valuation, though Bloomberg reported earlier this month that Isomorphic was seeking funds at a $50 billion value.
- The investment follows a $2.1 billion Series B round in May.
- Demis Hassabis has moved from CEO to chairman at DeepMind.
- Bloomberg reported a potential $50 billion valuation for the company.




